Genmab A/S (NASDAQ:GMAB) Shares Gap Down – Should You Sell?

Genmab A/S (NASDAQ:GMAB) shares gapped down prior to trading on Monday . The stock had previously closed at $19.76, but opened at $19.01. Genmab A/S shares last traded at $19.09, with a volume of 178,264 shares trading hands.

Wall Street Analysts Forecast Growth

GMAB has been the subject of a number of research reports. Leerink Partners upgraded Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 target price for the company in a report on Thursday, February 13th. BNP Paribas raised Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 11th. William Blair raised Genmab A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 11th. Leerink Partnrs upgraded shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Thursday, February 13th. Finally, HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a report on Thursday, January 23rd. Four research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Genmab A/S has a consensus rating of “Moderate Buy” and a consensus price target of $41.33.

Genmab A/S Price Performance

The stock has a market capitalization of $12.61 billion, a P/E ratio of 10.95, a price-to-earnings-growth ratio of 2.65 and a beta of 0.98. The company’s 50-day simple moving average is $20.94 and its 200-day simple moving average is $22.00.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. On average, analysts forecast that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Institutional Trading of Genmab A/S

Several institutional investors and hedge funds have recently bought and sold shares of the business. Charles Schwab Investment Management Inc. increased its holdings in shares of Genmab A/S by 94.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 26,104 shares of the company’s stock worth $636,000 after acquiring an additional 12,654 shares during the last quarter. Eagle Asset Management Inc. increased its holdings in shares of Genmab A/S by 10.0% in the third quarter. Eagle Asset Management Inc. now owns 12,356 shares of the company’s stock valued at $285,000 after purchasing an additional 1,121 shares during the last quarter. Cerity Partners LLC raised its position in shares of Genmab A/S by 14.6% in the third quarter. Cerity Partners LLC now owns 48,003 shares of the company’s stock valued at $1,170,000 after purchasing an additional 6,103 shares during the period. FMR LLC lifted its stake in shares of Genmab A/S by 13.5% during the 3rd quarter. FMR LLC now owns 278,194 shares of the company’s stock worth $6,782,000 after buying an additional 33,076 shares during the last quarter. Finally, Verition Fund Management LLC bought a new stake in shares of Genmab A/S during the 3rd quarter worth about $709,000. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.